Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Medicine & Life Sciences

• Poly(ADP-ribose) Polymerase Inhibitors 100%
• Homologous Recombination 14%
• Therapeutics 12%
• Neoplasms 12%
• Mutation 7%
• Synthetic Lethal Mutations 6%
• BRCA2 Gene 6%
• Poly (ADP-Ribose) Polymerase-1 5%
• BRCA1 Gene 5%
• Recombinational DNA Repair 5%
• Genomic Instability 4%
• Platinum 4%
• United States Food and Drug Administration 4%
• DNA Repair 3%
• Ovarian Neoplasms 3%
• Progression-Free Survival 3%
• Therapeutic Uses 3%
• Meta-Analysis 3%
• Maintenance 2%
• Clinical Trials 2%
• Breast Neoplasms 2%
• Population 1%
• Proteins 1%

Chemical Compounds

• Mutation 47%
• Resistance 47%
• Poly(ADPribose) 25%
• Protein 7%